Clinical Trial Update: hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating cabozantinib and durvalumab in bladder carcinoma (ARCADIA study) with status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Bladder Carcinoma | Phase 2 | Status: UNKNOWN